about
Rheumatoid arthritis treatment: the earlier the better to prevent joint damageThe multifaceted aspects of interstitial lung disease in rheumatoid arthritisChronic pain: the burden of disease and treatment innovations.The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice.Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.20 years of experience with tumour necrosis factor inhibitors: what have we learned?Randomized controlled trials and real-world data: differences and similarities to untangle literature dataSystematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritisManagement of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitisClinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies2018 Update of the EULAR recommendations for the management of large vessel vasculitisThe impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritisCan hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a commThe conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'AntirheuAging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and ManagementSuccessful treatment with baricitinb in a patient with refractory cutaneous dermatomyositisDiagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by GuiNon-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et alPrevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drComorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et alImpact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritisCandidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by KobakLumbar spondylolisthesis associated with systemic sclerosis-related spinal calcinosis: an unusual clinical case
P50
Q26777903-C8A11D72-355E-445F-9F05-22C7BC5D5A16Q26861557-61D200AB-05CB-40AB-82F0-25693EDCF4B3Q38613998-78B7AAD1-D2C8-43EE-8E88-ED301DE91720Q47605794-7CFADB1E-F0F3-4012-B64C-26FCBC80273FQ48112019-6CCF32EB-145F-4455-A28B-55717352CA6AQ57062391-09387DBA-416A-47B4-A173-378DF665731BQ57062393-AB2E8D4B-E352-480B-B4C9-15D6C70882DEQ91047108-5B265D06-7A90-4CA2-99C6-1AAD91580B34Q91047130-BB147D6A-4393-48BC-98AC-F7FE66A45033Q91519954-73E67302-CF29-460A-9B23-4D9EDDEB4ADEQ91591855-6038700F-B3A6-45A2-8817-234A52696630Q92061055-061A5961-7AED-4F1A-BB4E-D3717038353DQ93194431-8AE40950-FD54-4DE0-8CC0-2E7047BFE07CQ93266954-7815CBAB-ACD5-4058-8182-12947088E016Q93360577-1E176D70-39F9-4950-835C-7D1D631687F0Q94470590-4683A6D8-4596-4F08-A34C-E54CCAED07E6Q94473018-ABD4F2C8-1A6A-486B-97E8-8AC20FD7D936Q94473020-EBA67452-87C8-432F-8CA2-321D577D3AAAQ94947676-7AF44995-5C61-4DE4-8E93-5D44466F84A0Q95336168-073FA81F-BCF7-4346-AE88-0C6FBD82A73CQ95654542-4AB42302-36B9-42CE-9830-E95526773BB5Q96171124-67093E7D-8EED-4DCA-BF76-E4B01B8A00C7Q96580179-8D032942-96AF-41BD-8CEA-4D09FEBFD660
P50
description
researcher ORCID ID = 0000-0002-1800-6772
@en
wetenschapper
@nl
name
Sara Monti
@ast
Sara Monti
@en
Sara Monti
@es
Sara Monti
@nl
type
label
Sara Monti
@ast
Sara Monti
@en
Sara Monti
@es
Sara Monti
@nl
prefLabel
Sara Monti
@ast
Sara Monti
@en
Sara Monti
@es
Sara Monti
@nl
P106
P21
P31
P496
0000-0002-1800-6772